Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits

Executive Summary

Phase IIb interim look shows liver enzyme reductions, signs of glycemic control and no increase in peripheral edema from baseline. Cirius expects to have final data in the second half of 2019.


Related Content

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas
Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO
Finance Watch: Investors Can't Get Enough Of NASH, Including Start-Ups With Novel Drugs
Cirius Suspects Insulin Resistance Is Underlying Key To NASH


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts